For individuals identified as high-risk, such as those with elevated proportions of CD19 on IgD(+) CD24(−) B cells or abnormal levels of 7-hoca, early interventions like immunomodulators or metabolic interventions could potentially reduce the risk of glioma development. This evidence concerns the gene CD19 and glioma.